Medical Condition News

RSS

AstraZeneca commences NKTR-118 Phase III clinical programme for opioid-induced constipation

AstraZeneca today announced enrolment of the first patient in the Phase III clinical programme for NKTR-118, an oral peripherally-acting opioid antagonist being investigated for the treatment of opioid-induced constipation (OIC).

16 Mar 2011

Post-stroke depression management can lead to better physical functioning

Stroke patients who are not successfully treated for depression are at higher risk of losing some of their capability to function normally, according to a study in the March 15, 2011 issue of the journal Neurology.

16 Mar 2011

Nuclear fallout-related health fears rise in Japan

Concerns regarding health risks "rose dramatically in Japan Tuesday" after officials said more radiation was released at a nuclear power plant that was damaged in the tsunami, the Associated Press reports. In an address to the nation, Prime Minister Naoto Kan said radiation had been emitted from four reactors. "The level seems very high, and there is still a very high risk of more radiation coming out," he said.

16 Mar 2011

Hydro-stomach CT imaging is not a reliable tool for EGC detection: Study

Traditionally, both air and tap water have been used as oral contrast agents to achieve adequate gastric distension for preoperative computed tomography imaging in patients with early gastric cancer.

16 Mar 2011

Study investigates physiological changes within brain due to Prozac treatment

Selective serotonin reuptake inhibitors (SSRI) such as Prozac are regularly used to treat severe anxiety and depression. They work by immediately increasing the amount of serotonin in the brain and by causing long term changes in brain function. However it can take weeks of treatment before a patient feels any effect and both beneficial effects and side effects can persist after treatment is stopped.

16 Mar 2011

Self-sample HPV test can help increase cervical screening uptake among women

Home tests for the human papillomavirus could help increase the take-up of cervical screening among women who do not respond to screening invitations, new research shows today.

16 Mar 2011

Millennium, SGEN expand ADC collaboration

Seattle Genetics, Inc. announced today that Millennium: The Takeda Oncology Company, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, has paid an undisclosed fee to exercise an option to designate a second antigen target under the parties' existing antibody-drug conjugate (ADC) collaboration.

16 Mar 2011

Unigene initiates oral PTH Phase 2 study in postmenopausal women with osteoporosis

Unigene Laboratories, Inc. a leader in the design, delivery, manufacture and development of peptide-based therapeutics announced today the dosing of the first subject in a Phase 2 study with an experimental oral parathyroid hormone analog for the treatment of osteoporosis in postmenopausal women.

16 Mar 2011

Study underscores need for monitoring vitamin D levels in all cirrhosis patients

Vitamin D deficiency is a well reported complication in chronic cholestatic liver disease such as primary biliary cirrhosis. While the prevalence and treatment of this deficiency has been addressed in many articles over the last decades, little is known of the vitamin D status in alcoholic liver cirrhosis.

16 Mar 2011

Enzo Life Sciences introduces ELISA system to detect SMN protein

Enzo Biochem, Inc. and the Spinal Muscular Atrophy Foundation today announced that Enzo's wholly owned subsidiary, Enzo Life Sciences Inc., has launched a unique immunoassay system which can be used for the identification and detection of Survival Motor Neuron protein.

16 Mar 2011

15 million people caring for 5 million Alzheimer’s sufferers: U.S. report card

According to a report released on Tuesday by the Alzheimer's Association, nearly 15 million Americans are now caring for a family member or friend with Alzheimer's disease or related dementias. The Association warns that these figures may rise if new therapies for Alzheimer’s are not found.

15 Mar 2011

Heavy drinking related to pancreatic cancer: Study

According to the latest research, heavy drinkers have an increased risk of dying from pancreatic cancer. The study has shown that non-smokers who have three or more drinks of hard liquor a day face a 36 percent higher risk of dying from pancreatic cancer, compared with non-drinkers. Smoking is a definite risk for pancreatic cancer. The report is published in the March 14 issue of the Archives of Internal Medicine.

15 Mar 2011

Depressed, older people who have a stroke are more likely to be dependent

People who have a stroke are more likely to be dependent if they are depressed, older or have other medical problems, according to a study published in the March 15, 2011, print issue of Neurology®, the medical journal of the American Academy of Neurology.

15 Mar 2011

Argon acquires global rights to market, distribute Rex Medical's Option Retrievable Inferior Vena Cava Filter

Argon Medical Devices, Inc. announced today that it has entered into a definitive license agreement with Rex Medical, LP ("Rex Medical") for exclusive global rights to market and distribute the Option™ Retrievable Inferior Vena Cava Filter, an implantable device used in the prevention of Pulmonary Embolism (PE).

15 Mar 2011

Research links frequent prescribing to opioid-related deaths

Some physicians are prescribing opioids such as OxyContin 55 times as often as others, according to a new study led by St. Michael's Hospital and the Institute for Clinical Evaluative Sciences (ICES). The study found most opioid-related deaths occur among patients treated by physicians who frequently prescribe opioids, suggesting doctors who prescribe a lot of opioids may not be doing so safely.

15 Mar 2011

AYA cancer patients require targeted care, say experts

Adolescents and young adults are neither children nor adults and those affected by cancer require targeted care that crosses the boundaries between pediatric and adult oncology, according to several pioneers in this still-developing field of adolescent and young adult oncology.

15 Mar 2011

Researchers receive NIH grant to study effects of BBTW treatment in patients with MS

Motion Therapeutics, Inc., the leading provider of noninvasive therapeutic solutions for balance and mobility disorders, today announced that researchers at Samuel Merritt University and San Francisco State received a NIH Recovery Act Grant to study the effects of wearing a strategically weighted vest to improve gait and mobility in people with MS.

15 Mar 2011

CLL patients receive Biothera's new combination therapy in Phase I/II clinical trial

Patients with earlier stage high-risk Chronic Lymphocytic Leukemia recently began receiving a new combination treatment in a Phase I/II clinical trial that researchers believe could result in a more effective therapy for this disease, Biothera announced today.

15 Mar 2011

Incyte’s ruxolitinib COMFORT-II Phase III trial in MF meets primary endpoint

COMFORT-II, the second pivotal Phase III trial of Incyte Corporation's investigational Janus kinase inhibitor, ruxolitinib, has met its primary endpoint of significantly reducing spleen size in patients with myelofibrosis, when compared to best available therapy.

15 Mar 2011

Chelsea uses PHT's LogPad, SitePad Tablet for clinical study to treat Parkinson's patients with NOH

PHT Corporation announced that Chelsea Therapeutics is using PHT's LogPad System and SitePad Tablet for its ongoing clinical study in Parkinson's disease patients with symptomatic neurogenic orthostatic hypotension.

15 Mar 2011